Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin

Cancer Research

Volumn 63, Issue 12, 2003, Pages 3228-3233

  Rajendra, Rajeev ^a   Gounder, Murugesan K ^a   Saleem, Ahamed ^a   Schellens, Jan H M ^c   Ross, Douglas D ^d   Bates, Susan E ^e   Sinko, Patrick ^b   Rubin, Eric H ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b School of Pharmacy ^*  (United States)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; ARGININE; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN DERIVATIVE; CELL PROTEIN; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MUTANT PROTEIN; RUBITECAN; THREONINE; TOPOTECAN; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CELL LINE; CELL PROLIFERATION; CELL TRANSPORT; CYTOTOXICITY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG TRANSPORT; GENE OVEREXPRESSION; MAMMAL CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FAMILY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; CELL DIVISION; DOGS; DRUG RESISTANCE, NEOPLASM; HUMANS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; RECOMBINANT FUSION PROTEINS; SELECTION (GENETICS); TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0038069097     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Liu, L. F. DNA topoisomerase poisons antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
2. Rubin, E. H. and Hait, W. W. Anthracyclines and DNA intercalators/epipodophyllotoxins/DNA topoisomerases. In: R. C. Bast (ed.). Cancer Medicine 5. pp. 670-679. B. C. Decker, 2000.
3. Wani, M. C., Nicholas, A. W., and Wall, M. E. Plant antitumor agents. Synthesis and antileukemia activity of camptothecin analogs. J. Med. Chem., 29: 2358-2363, 1986.
4. Wani, M. C., Nicholas, A. W., Manikumar, G., and Wall, M. E. Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations. J. Med. Chem., 30: 1774-1779, 1987.
5. Ellerhorst, J. A., Bedikian, A. Y., Smith, T. M., Papadopoulos, N. E., Plager, C., and Eton, O. Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma. Anticancer Drugs, 13: 169-172, 2002.
6. Konstadoulakis, M. M., Antonakis, P. T., Tsibloulis, B. G., Stathopoulos, G. P., Manouras, A. P., Mylonaki, D. B., and Golematis, B. X. A Phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother. Pharmacol., 48: 417-420, 2001.
7. Stehlin, J. S., Giovanella, B. C., Natelson, E. A., De Ipolyi, P. D., Coil, D., Davis, B., Wolk, D., Wallace, P., and Trojacek, A. A study of 9-nitrocamptothecin (RFS 2000) in patients with advanced pancreatic cancer. Int. J. Oncol., 14: 821-831, 1999.
8. Verschraegen, C. F., Gupta, E., Loyer, E., Kavanagh, J. J., Kudelka, A. P., Freedman, R. S., Edwards, C. L., Harris, N., Steger, M., Steltz, V., Giovanella, B. C., and Stehlin, J. S. A Phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drags, 10: 375-383, 1999.
9. Argiris, A., Heald, P., Kuzel, T., Foss, F. M., DiStasio, S., Cooper, D. L., Arbuck, S., and Murren, J. R. Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma. Invest. New Drugs, 19: 321-326, 2001.
10. Kraut, E. H., Balcerzak, S. P., Young, D., O'Rourke, M. A., Petrus, J. J., Kuebler, J. P., and Mayemik, D. G. A Phase II study of 9-aminocamptothecin in patients with refractory breast cancer. Cancer Invest., 18: 28-31, 2000.
11. Pazdur, R., Diaz-Canton, E., Ballard, W. P., Bradof, J. E., Graham, S., Arbuck, S. G., Abbruzzese, J. L., and Winn, R. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. J. Clin. Oncol., 15: 2905-2909, 1997.
12. Pazdur, R., Medgyesy, D. C., Winn, R. J., Dakhil, S. R., Moore, D. F., Jr., Scalzo, A., Hoff, P. M., Arbuck, S. G., and Abbruzzese, J. L. Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma. Invest. New Drugs, 16: 341-346, 1998.
13. Vokes, E. E., Ansari, R. H., Masters, G. A., Hoffman, P. C., Klepsch, A., Ratain, M. J., Sciortino, D. F., Lad, T. E., Krauss, S., Fishkin, P. A., and Golomb, H. M. A Phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. Ann. Oncol., 9: 1085-1090, 1998.
14. Vokes, E. E., Gordon, G. S., Rudin, C. M., Mauer, A. M., Watson, S., Krauss, S., Arrieta, R., Golomb, H. M., and Hoffman, P. C. A Phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer. Invest. New Drugs, 19: 329-333, 2001.
15. Chen, A. Y., Yu, C., Potmesil, M., Wall, M. E., Wani, M. C., and Liu, L. F. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res., 51: 6039-6044, 1991.
16. Chen, Z. S., Furukawa, T., Sumizawa, T., Ono, K., Ueda, K., Seto, K., and Akiyama, S. I. ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol. Pharmacol., 55: 921-928, 1999.
17. Koike, K., Kawabe, T., Tanaka, T., Toh, S., Uchiumi, T., Wada, M., Akiyama, S., Ono, M., and Kuwano, M. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res., 57: 5475-5479, 1997.
18. Allikmets, R., Schriml, L. M., Hutchinson, A., Romano-Spica, V., and Dean, M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res., 58: 5337-5339, 1998.
19. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., and Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA, 95: 15665-15670, 1998.
20. Miyake, K., Mickley, L., Litman, T., Zhan, Z., Robey, R., Cristensen, B., Brangi, M., Greenberger, L., Dean, M., Fojo, T., and Bates, S. E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res., 59: 8-13, 1999.
21. Maliepaard, M., van Gastelen, M. A., de Jong, L. A., Pluim, D., van Waardenburg, R. C., Ruevekamp-Helmers, M. C., Floot, B. G., and Schellens, J. H. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res., 59: 4559-4563, 1999.
22. Allen, J. D., Brinkhuis, R. F., Wijnholds, J., and Schinkel, A. H. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res., 59: 4237-4241, 1999.
23. Yang, C. H., Schneider, E., Kuo, M. L., Volk, E. L., Rocchi, E., and Chen, Y. C. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem. Pharmacol., 60: 831-837, 2000.
24. Ross, D. D., Yang, W., Abruzzo, L. V., Dalton, W. S., Schneider, E., Lage, H., Dietel, M., Greenberger, L., Cole, S. P., and Doyle, L. A. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst. (Bethesda), 91: 429-433, 1999.
25. Honjo, Y., Hrycyna, C. A., Yan, Q. W., Medina-Perez, W. Y., Robey, R. W., van de Laar, A., Litman, T., Dean, M., and Bates, S. E. Acquired mutations in the MXR/ BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res., 61: 6635-6639, 2001.
26. Allen, J. D., Jackson, S. C., and Schinkel, A. H. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance. Cancer Res., 62: 2294-2299, 2002.
27. Robey, R. W., Honjo, Y., Morisaki, K., Nadjem, T. A., Runge, A., Risbood, M., Poruchynsky, M. S., and Bates, S. E. Distinctive drug resistance profile conferred by wild-type and mutant forms of ABCG2. Submitted.
28. Saleem, A., Ibrahim, N., Patel, M., Li, X. G., Gupta, E., Mendoza, J., Pantazis, P., and Rubin, E. H. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. Cancer Res., 57: 5100-5106, 1997.
29. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
30. Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C., Schinkel, A. H., an De Vijver, M. J., Scheper, R. J., and Schellens, J. H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res., 61: 3458-3464, 2001.
31. Rubin, E., Pantazis, P., Bharti, A., Toppmeyer, D., Giovanella, B., and Kufe, D. Identification of a mutant human topoisomerase 1 with intact catalytic activity and resistance to 9-nitro-camptothecin. J. Biol. Chem., 269: 2433-2439, 1994.
32. Gounder, M. K., Sun, S-L., and Rubin, E. H. Sensitive quantitation of 9-nitrocamtothecin (9-NC) in human plasma by enzymatic conversion to 9-aminocamtothecin (9-AC). Proc. Am. Assoc. Cancer Res., 43: 430, 2002.
33. Takimoto, C. H., Klecker, R. W., Dahut, W. L., Yee, L. K., Strong, J. M., Allegra, C. J., and Grem, J. L. Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J. Chromatogr. B Biomed. Appl., 655: 97-104, 1994.
34. Brangi, M., Litman, T., Ciotti, M., Nishiyama, K., Kohlhagen, G., Takimoto, C., Robey, R., Pommier, Y., Fojo, T., and Bates, S. E. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res., 59: 5938-5946, 1999.
35. Erlichman, C., Boemer, S. A., Hallgren, C. G., Spieker, R., Wang, X. Y., James, C. D., Scheffer, G. L., Maliepaard, M., Ross, D. D., Bible, K. C., and Kaufmann, S. H. The HER tyrosine kinase inhibitor CII033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance proteinmediated drug efflux. Cancer Res., 61: 739-748, 2001.
36. Andoh, T., Ishii, K., Suzuki, Y., Ikegami, Y., Kusunoki, Y., Takemoto, Y., and Okada, K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase 1. Proc. Natl. Acad. Sci. USA, 84: 5565-5569, 1987.
37. Reid, R. J., Kauh, E. A., and Bjomsti, M. A. Camptothecin sensitivity is mediated by the pleiotropic drug resistance network in yeast. J. Biol. Chem., 272: 12091-12099, 1997.
38. Lage, H., and Dietel, M. Effect of the breast-cancer resistance protein on atypical multidrug resistance. Lancet Oncol., 1: 169-175, 2000.
39. Schellens, J. H., Maliepaard, M., Scheper, R. J., Scheffer, G. L., Jonker, J. W., Smit, J. W., Beijnen, J. H., and Schinkel, A. H. Transport of topoisomerase 1 inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann. N. Y. Acad. Sci., 922: 188-194, 2000.
40. Bates, S. E., Robey, R., Miyake, K., Rao, K., Ross, D. D., and Litman, T. The role of half-transporters in multidrug resistance. J. Bionerg. Biomembr., 33: 503-511, 2001.
41. Ozvegy, C., Litman, T., Szakacs, G., Nagy, Z., Bates, S., Varadi, A. and Sarkadi, B. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem. Biophys. Res. Commun., 285: 111-117, 2001.
42. Ross, D. D., Karp, J. E., Chen, T. T., and Doyle, L. A. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood, 96: 365-368, 2000.
43. Sargent, J. M., Williamson, C. J., Maliepaard, M., Elgie, A. W., Scheper, R. J., and Taylor, C. G. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br. J. Haematol., 115: 257-262, 2001.
44. Sauerbrey, A., Sell, W., Steinbach, D., Voigt, A., and Zintl, F. Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br. J. Haematol., 118, 147-150, 2002.
45. Steinbach, D., Sell, W., Voigt, A., Hermann, J., Zintl, F., and Sauerbrey, A. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia (Baltimore), 16: 1443-1447, 2002.
46. Maliepaard, M., van Gastelen, M. A., Tohgo, A., Hausheer, F. H., van Waardenburg, R. C., de Jong, L. A., Pluim, D., Beijnen, J. H., and Schellens, J. H. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin. Cancer Res., 7: 935-941, 2001.
47. Perego, P., De Cesare, M., De Isabella, P., Carenini, N., Beggiolin, G., Pezzoni, G., Palumbo, M., Tartaglia, L., Pratesi, G., Pisano, C., Carminati, P., Scheffer, G. L., and Zunino, F. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res., 61: 6034-6037, 2001.
48. Louvard, D. Apical membrane aminopeptidase appears at site of cell-cell contact in cultured kidney epithelial cells. Proc. Natl. Acad. Sci. USA, 77: 4132-4136, 1980.
49. Pastan, I., Gottesman, M. M., Ueda, K., Lovelace, E., Rutherford, A. V., and Willingham, M. C. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc. Natl. Acad. Sci. USA, 85: 4486-4490, 1988.
50. Bakos, E., Evers, R., Szakacs, G., Tusnady, G. E., Welker, E., Szabo, K., de Haas, M., van Deemter, L., Borst, P., Varadi, A., and Sarkadi, B. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J. Biol. Chem., 273: 32167-32175, 1998.
51. Evers, R., Kool, M., van Deemter, L., Janssen, H., Calafat, J., Oomen, L. C., Paulusma, C. C., Oude Elferink, R. P., Baas, F., Schnikel, A. H., and Borst, P. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Investig., 101: 1310-1319, 1998.